Show simple item record

Antibodies, boosters and optimizing SARS-CoV-2 vaccine for transplantation: A call for more research

dc.contributor.authorIson, Michael G.
dc.contributor.authorBlumberg, Emily
dc.contributor.authorHalasa, Natasha
dc.contributor.authorKaul, Dan
dc.contributor.authorTheodoropoulos, Nicole M.
dc.contributor.authorWolfe, Cameron R.
dc.date2022-08-11T08:08:10.000
dc.date.accessioned2022-08-23T15:45:07Z
dc.date.available2022-08-23T15:45:07Z
dc.date.issued2021-07-09
dc.date.submitted2021-07-13
dc.identifier.citation<p>Ison MG, Blumberg E, Halasa N, Kaul D, Theodoropoulos NM, Wolfe CR. Antibodies, boosters and optimizing SARS-CoV-2 vaccine for transplantation: A call for more research. Am J Transplant. 2021 Jul 9. doi: 10.1111/ajt.16758. Epub ahead of print. PMID: 34241964. <a href="https://doi.org/10.1111/ajt.16758">Link to article on publisher's site</a></p>
dc.identifier.issn1600-6135 (Linking)
dc.identifier.doi10.1111/ajt.16758
dc.identifier.pmid34241964
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27456
dc.description.abstractDespite emerging data suggesting reduced antibody responses among SOT recipients following SARS-CoV-2 vaccine, critical unanswered questions remain. The clinical implications of the reduced humoral response need to be assessed through prospective studies. Studies are likewise needed to inform which vaccine dosing strategies result in improved immunity and if such approaches maximize protection against severe infection in the vulnerable transplant population.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=34241964&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsThis article is protected by copyright. All rights reserved. This is a PDF file of an accepted manuscript that has been accepted for publication and posted with a 12-month embargo as allowed by the publisher’s author rights policy at https://authorservices.wiley.com/author-resources/Journal-Authors/licensing/self-archiving.html. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectvaccine
dc.subjectantibodies
dc.subjectantibody response
dc.subjectImmunology of Infectious Disease
dc.subjectImmunoprophylaxis and Therapy
dc.subjectImmunotherapy
dc.subjectInfectious Disease
dc.subjectMicrobiology
dc.subjectSurgical Procedures, Operative
dc.subjectVirus Diseases
dc.titleAntibodies, boosters and optimizing SARS-CoV-2 vaccine for transplantation: A call for more research
dc.typeAccepted Manuscript
dc.source.journaltitleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1260&amp;context=covid19&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/256
dc.legacy.embargo2022-07-09T00:00:00-07:00
dc.identifier.contextkey23809037
refterms.dateFOA2022-08-23T15:45:07Z
html.description.abstract<p>Despite emerging data suggesting reduced antibody responses among SOT recipients following SARS-CoV-2 vaccine, critical unanswered questions remain. The clinical implications of the reduced humoral response need to be assessed through prospective studies. Studies are likewise needed to inform which vaccine dosing strategies result in improved immunity and if such approaches maximize protection against severe infection in the vulnerable transplant population.</p>
dc.identifier.submissionpathcovid19/256
dc.contributor.departmentDepartment of Medicine, Division of Infectious Diseases and Immunology


Files in this item

Thumbnail
Name:
ajt.16758.pdf
Size:
5.755Mb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record